These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30643869)

  • 1. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®).
    Coelho J; Pessoa B; Meireles A
    Ther Adv Ophthalmol; 2019; 11():2515841418820755. PubMed ID: 30643869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome.
    Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J
    Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
    Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
    Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema.
    Weber LF; Marx S; Auffarth GU; Scheuerle AF; Tandogan T; Mayer C; Khoramnia R
    J Ophthalmic Inflamm Infect; 2019 Jan; 9(1):3. PubMed ID: 30694420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN
    Carneiro A; Meireles A; Castro Sousa JP; Teixeira C
    Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
    Currie CJ; Holden SE; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
    Panos GD; Arruti N; Patra S
    Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Fluocinolone Acetonide Implant (ILUVIEN
    Mushtaq Y; Mushtaq MM; Gatzioufas Z; Ripa M; Motta L; Panos GD
    Drug Des Devel Ther; 2023; 17():961-975. PubMed ID: 37020801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
    Soubrane G; Behar-Cohen F
    J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
    Sanford M
    Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
    Adams OE; Schechet SA; Hariprasad SM
    Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
    Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
    Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
    Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Diabetic Macular Edema: What to Do.
    Gonçalves RS; Teixeira C; Coelho P
    Case Rep Ophthalmol; 2017; 8(3):465-474. PubMed ID: 29118706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.